Sai Parenterals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter
Sai Parenterals Ltd · Others (Uncategorized) · 01 Nov 2026, 11:37 pm
Sai Parenterals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter Sai Parenterals confirmed zero deviation or variation in utilizing proceeds from its ₹2,850 million IPO for the quarter ended 30th Sep'26, as monitored by India Ratings & Research. Key fund deployments include ₹356.41 million for subsidiary bridge and term loan repayments, ₹330.00 million for working capital, and ₹284.90 million for issue expenses. The company allocated ₹838.34 million (₹100 million utilized) for a 60% equity stake in Saicriti Pharma to construct an injectable facility, alongside ₹150 million utilized for a 60% stake in Prathyak Laboratories.
Original exchange filing (PDF)
More announcements from Sai Parenterals Ltd
- Press Release by Sai Parenteral''s Limited · 17 Nov 2026
- Outcome of Board Meeting held on Monday, 16th November, 2026 · 17 Nov 2026
- call conducted on Monday the 2nd day of November, 2026. · 07 Nov 2026
- Audio recording of earning call held on 2nd November, 2026 over call. · 03 Nov 2026
- Investor Presentation for the quarter and half year ended 30th September, 2026 · 02 Nov 2026
- Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th September, 2026. · 01 Nov 2026
- Financial Results · 01 Nov 2026
- Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 01 Nov 2026
